Bushi Wang

3.8k total citations · 2 hit papers
24 papers, 1.9k citations indexed

About

Bushi Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, Bushi Wang has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Statistics and Probability. Recurrent topics in Bushi Wang's work include Lung Cancer Treatments and Mutations (9 papers), Statistical Methods in Clinical Trials (7 papers) and Optimal Experimental Design Methods (6 papers). Bushi Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Statistical Methods in Clinical Trials (7 papers) and Optimal Experimental Design Methods (6 papers). Bushi Wang collaborates with scholars based in United States, Germany and Canada. Bushi Wang's co-authors include Frank W. Sellke, Menno V. Huisman, Stephan Glund, Elaine M. Hylek, Paul A. Reilly, John W. Eikelboom, Pieter W. Kamphuisen, Jeffrey I. Weitz, Thorsten Steiner and Charles V. Pollack and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Bushi Wang

24 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Idarucizumab for Dabigatran Reversal

2015 981 citations Charles V. Pollack, Paul A. Reilly et al. New England Journal of Medicine profile →
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

2015 324 citations Jean‐Charles Soria, Enriqueta Felip et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bushi Wang United States	10	901	675	649	560	288	24	1.9k
David D. Stenehjem United States	18	318 0.4×	402 0.6×	438 0.7×	626 1.1×	318 1.1×	113	1.8k
Anders Själander Sweden	24	991 1.1×	85 0.1×	491 0.8×	452 0.8×	307 1.1×	81	1.9k
Max‐Paul Winter Austria	23	798 0.9×	397 0.6×	199 0.3×	110 0.2×	247 0.9×	72	1.7k
Murray M. Bern United States	18	351 0.4×	410 0.6×	472 0.7×	216 0.4×	128 0.4×	61	1.5k
Nancy Cook‐Bruns Germany	9	1.5k 1.6×	416 0.6×	725 1.1×	188 0.3×	60 0.2×	10	2.2k
Christelle Darstein United States	14	717 0.8×	161 0.2×	186 0.3×	187 0.3×	185 0.6×	36	1.3k
Carlos Jerjes‐Sánchez Mexico	19	878 1.0×	682 1.0×	490 0.8×	61 0.1×	94 0.3×	87	1.7k
Franco Buzzi Italy	19	314 0.3×	415 0.6×	412 0.6×	1.0k 1.8×	264 0.9×	42	1.9k
Philip W. Friederich Netherlands	19	453 0.5×	194 0.3×	547 0.8×	156 0.3×	122 0.4×	23	2.0k
Florence Le Maulf United States	10	656 0.7×	409 0.6×	636 1.0×	76 0.1×	75 0.3×	19	1.3k

Countries citing papers authored by Bushi Wang

Since Specialization

Citations

This map shows the geographic impact of Bushi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bushi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bushi Wang more than expected).

Fields of papers citing papers by Bushi Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bushi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bushi Wang. The network helps show where Bushi Wang may publish in the future.

Co-authorship network of co-authors of Bushi Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Bushi Wang. A scholar is included among the top collaborators of Bushi Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bushi Wang. Bushi Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolcher, Anthony W., Navid Hafez, Noboru Yamamoto, et al.. (2020). A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3660–TPS3660. 1 indexed citations

Luciani, Matteo, Manuela Albisetti, Branislav Biss, et al.. (2018). Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. Research and Practice in Thrombosis and Haemostasis. 2(3). 580–590. 9 indexed citations

Albisetti, Manuela, Branislav Biss, Lisa Bomgaars, et al.. (2018). Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Research and Practice in Thrombosis and Haemostasis. 2(2). 347–356. 13 indexed citations

Felip, Enriqueta, Vera Hirsh, Sanjay Popat, et al.. (2017). Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer. 19(1). 74–83.e11. 25 indexed citations

Horn, Leora, Scott Gettinger, D. Ross Camidge, et al.. (2017). Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer. 113. 51–58. 15 indexed citations

Wang, Bushi & Xinping Cui. (2017). An improved uniformly more powerful exact Fisher–Hayter pairwise comparisons procedure. Biometrical Journal. 59(4). 767–775. 5 indexed citations

Burtness, Barbara, Robert I. Haddad, José Dinis, et al.. (2017). LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 6001–6001. 9 indexed citations

Lin, Jianchang, et al.. (2016). Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. DIAL (Catholic University of Leuven). 5 indexed citations

Reilly, Paul A., Richard A. Bernstein, Robert Dubiel, et al.. (2015). Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis. 114(7). 198–205. 109 indexed citations

10.

Pollack, Charles V., Paul A. Reilly, John W. Eikelboom, et al.. (2015). Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 373(6). 511–520. 981 indexed citations breakdown →

11.

Soria, Jean‐Charles, Enriqueta Felip, Manuel Cobo, et al.. (2015). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. The Lancet Oncology. 16(8). 897–907. 324 indexed citations breakdown →

12.

Soria, Jean‐Charles, Enriqueta Felip, Manuel Cobo, et al.. (2015). Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).. Journal of Clinical Oncology. 33(15_suppl). 8002–8002. 10 indexed citations

13.

Pollack, Charles V., Paul Reilly, John W. Eikelboom, et al.. (2015). Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad Trial. Circulation. 132(suppl_3). 5 indexed citations

14.

Janjigian, Yelena Y., Egbert F. Smit, Harry J.M. Groen, et al.. (2014). Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery. 4(9). 1036–1045. 295 indexed citations

15.

Wang, Bushi & Naitee Ting. (2014). An Application of Graphical Approach to Construct Multiple Testing Procedures in a Hypothetical Phase III Design. Frontiers in Public Health. 1. 75–75. 2 indexed citations

16.

Wang, Bushi & Xinping Cui. (2012). A new partition testing strategy for multiple endpoints. Statistics in Medicine. 31(20). 2151–2168. 2 indexed citations

17.

Kim, Joo-Hang, Francesco Grossi, Filippo de Marinis, et al.. (2012). Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. Journal of Clinical Oncology. 30(15_suppl). 7558–7558. 9 indexed citations

18.

Schüler, Martin, David Planchard, James Chih‐Hsin Yang, et al.. (2012). Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.. Journal of Clinical Oncology. 30(15_suppl). 7557–7557. 16 indexed citations

19.

Wang, Bushi, et al.. (2010). General solutions to consistency problems in multiple hypothesis testing. Biometrical Journal. 52(6). 735–746. 5 indexed citations

20.

Wang, Bushi & Xinping Cui. (2010). Consonant closed likelihood ratio test procedures with application to dose–response study. Statistics in Medicine. 29(25). 2617–2630. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact